Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daria Hazuda

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|July 2, 2008
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistanceJacob A Zahm, Sibes Bera, Krishan K Pandey, et al.
Journal of Virology|September 18, 2009
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathwaysSigne Fransen, Soumi Gupta, Robert Danovich, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2009
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitorsAndrea Low, Nicole Prada, Michael Topper, et al.
Antimicrobial Agents and Chemotherapy|May 14, 2008
Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infectionKatty Terrazas-Aranda, Yven Van Herrewege, Daria Hazuda, et al.
Plos One|March 31, 2011
The base excision repair pathway is required for efficient lentivirus integrationKristine E Yoder, Amy Espeseth, Xiao-hong Wang, et al.
Antiviral Therapy|May 25, 2016
Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screeningRichard Barnard, Abha Chopra, Ian James, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2021
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical IsolatesErnest Asante-Appiah, Johnny Lai, Hong Wan, et al.
Journal of Neurochemistry|November 23, 2005
A presenilin-independent aspartyl protease prefers the gamma-42 site cleavageMing-Tain Lai, Ming-Chih Crouthamel, Jillian DiMuzio, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzeesSteven S Carroll, Steven Ludmerer, Larry Handt, et al.
Antimicrobial Agents and Chemotherapy|December 1, 2010
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agentsDavid B Olsen, Mary-Ellen Davies, Larry Handt, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|July 2, 2008
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistanceJacob A Zahm, Sibes Bera, Krishan K Pandey, et al.
Journal of Virology|September 18, 2009
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathwaysSigne Fransen, Soumi Gupta, Robert Danovich, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2009
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitorsAndrea Low, Nicole Prada, Michael Topper, et al.
Antimicrobial Agents and Chemotherapy|May 14, 2008
Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infectionKatty Terrazas-Aranda, Yven Van Herrewege, Daria Hazuda, et al.
Plos One|March 31, 2011
The base excision repair pathway is required for efficient lentivirus integrationKristine E Yoder, Amy Espeseth, Xiao-hong Wang, et al.
Antiviral Therapy|May 25, 2016
Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screeningRichard Barnard, Abha Chopra, Ian James, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2021
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical IsolatesErnest Asante-Appiah, Johnny Lai, Hong Wan, et al.
Journal of Neurochemistry|November 23, 2005
A presenilin-independent aspartyl protease prefers the gamma-42 site cleavageMing-Tain Lai, Ming-Chih Crouthamel, Jillian DiMuzio, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzeesSteven S Carroll, Steven Ludmerer, Larry Handt, et al.
Antimicrobial Agents and Chemotherapy|December 1, 2010
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agentsDavid B Olsen, Mary-Ellen Davies, Larry Handt, et al.
Pageof 6